Últimas noticias sobre Eterna Therapeutics (NASDAQ:ERNA) Bolsa

Eterna Therapeutics

Eterna Therapeutics Inc is a biopharmaceuticals company. The company develops transformational new medicines using various cell engineering technology. It is engaged in developing breakthrough mRNA cell engineering technologies to repair cellular dysfunction and treat a range of therapeutic indications. With its strategic partners, the group is developing nucleic acid and cell therapies that can significantly improve the health outcomes of patients with high unmet medical needs.

Eterna Therapeutics Inc

WIIM

ECARX Holdings shares are trading higher after the company announced a plan to repurchase up to $20 million of its ordinary shares through September 30, 2025.

JP Morgan analyst Matthew Boss maintains Abercrombie &amp; Fitch (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ANF#NYSE">ANF</a>) with a Overweight and raises the price target from $201 to $204.

News

Price Target

Analyst Ratings

JP Morgan Maintains Overweight on Abercrombie & Fitch, Raises Price Target to $204

WEX (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WEX#NYSE">WEX</a>) has outperformed the market over the past 15 years by 31.59% on an annualized basis producing an average annual return of 43.27%. Currently, WEX has a market capitalization of $6.66 billion. 
Buying $1000 In WEX: If an investor had bought $1000 of WEX stock 15 years ago, it would be worth $219,844.16 today based on a price of $167.45 for WEX at the time of writing.
<h3>WEX's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734711614_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

$1000 Invested In This Stock 15 Years Ago Would Be Worth This Much Today

JP Morgan analyst Rajat Gupta maintains CarMax (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KMX#NYSE">KMX</a>) with a Underweight and raises the price target from $70 to $72.

JP Morgan Maintains Underweight on CarMax, Raises Price Target to $72

TD Cowen analyst Daniel Chan upgrades BlackBerry (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BB#NYSE">BB</a>) from Hold to Buy and raises the price target from $3.25 to $4.

Upgrades

TD Cowen Upgrades BlackBerry to Buy, Raises Price Target to $4

JP Morgan analyst Brian Ossenbeck maintains FedEx (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FDX#NYSE">FDX</a>) with a Overweight and raises the price target from $366 to $370.

JP Morgan Maintains Overweight on FedEx, Raises Price Target to $370

Mastercard's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MA#NYSE">MA</a>) short percent of float has risen 5.48% since its last report. The company recently reported that it has 6.29 million shares sold short, which is 0.77% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.31 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Mastercard Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734711325_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Mastercard has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Mastercard's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Mastercard's peer group average for short interest as a percentage of float is 4.86%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Peering Into Mastercard's Recent Short Interest

Viking Therapeutics's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VKTX#NYSE">VKTX</a>) short percent of float has risen 6.35% since its last report. The company recently reported that it has 18.07 million shares sold short, which is 21.78% of all regular shares that are available for trading. Based on its trading volume, it would take traders 5.08 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Viking Therapeutics Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734711319_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Viking Therapeutics has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Viking Therapeutics's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Viking Therapeutics's peer group average for short interest as a percentage of float is 13.65%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

VKTX

Looking Into Viking Therapeutics's Recent Short Interest

Lumentum Holdings's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LITE#NYSE">LITE</a>) short percent of float has risen 5.18% since its last report. The company recently reported that it has 11.15 million shares sold short, which is 21.74% of all regular shares that are available for trading. Based on its trading volume, it would take traders 5.96 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Lumentum Holdings Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734711315_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Lumentum Holdings has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Lumentum Holdings's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Lumentum Holdings's peer group average for short interest as a percentage of float is 6.05%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

LITE

Peering Into Lumentum Holdings's Recent Short Interest

Macro Economic Events

Market Summary

Economics

General

Benzinga Market Summary: Novo Nordisk Falls On Weight Loss Data, Shares Of Competitor Lilly Rise, S&P Continues Higher

DXCM

Shares of glucose monitoring stocks are trading higher following weaker-than-expected weight loss data from Novo Nordisk.

Pyxis Oncology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PYXS#NASDAQ">PYXS</a>) announced on Thursday, a portfolio prioritization, focusing resources on advancing its <a href="https://www.benzinga.com/pressreleases/24/12/g42603862/pyxis-oncology-announces-portfolio-prioritization-focusing-resources-on-its-lead-clinical-program-" target="_blank" rel="noreferrer noopener">lead clinical program, PYX-201</a>.
Pyxis Oncology&#8217;s second clinical program, PYX-106, is being deprioritized to allocate resources toward advancing the lead asset, PYX-201.
As a result, Pyxis Oncology has decided to suspend further clinical investment in PYX-106, which was in-licensed from Biosion Inc., with Biosion retaining rights for Greater China.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/11/42113042/pyxis-oncologys-cancer-drug-progress-stirs-analyst-concerns" rel="noreferrer noopener">Pyxis Oncology&#8217;s Cancer Drug Progress Stirs Analyst Concerns</a>
In November, Pyxis Oncology reported preliminary data from the ongoing Phase 1 dose-escalation study of PYX-201, evaluating its safety and efficacy in multiple solid tumor types.
Among patients with HNSCC, PYX-201 achieved a confirmed 50% objective response rate (ORR), including one complete response and a disease control rate (DCR) of 100% in six heavily pretreated HPV-positive and HPV-negative evaluable patients with a median of four prior lines of therapy.
Across six solid tumor types of interest at therapeutically active dose levels, including HNSCC, ovarian, non-small cell lung cancer (NSCLC), HR+/HER2- breast cancer, triple-negative breast cancer (TNBC) and sarcoma, PYX-201 (n=31) achieved a 26% ORR in the Phase 1 trial, with dose-dependent responses observed.
The portfolio prioritization further supports a development plan for PYX-201 in several dose expansion studies, including monotherapy in 2/3L HNSCC, in combination with pembrolizumab in 1/2L+ HNSCC, and pembrolizumab combination studies in other solid tumors including HR+/HER2- and triple-negative breast cancer.
Preliminary data from these cohorts are expected in the second half of 2025 and the first half of 2026.
&#8220;Given the historical development challenges associated with anti-siglec-15 antibodies, we believe that the Street expectations were low heading into the initial data readout for PYX-106,&#8221; said the William Blair analyst.
The company&#8217;s current cash position is expected to fund its planned monotherapy and combination therapy trials of PYX-201 into the second half of 2026.
The analyst says it supports management's decision to stop investing in the program. While PYX-201 showed some activity, it likely won't significantly change head and neck cancer treatment.
PYXS Price Action: PYXS Oncology stock is up 1.30% at $1.56 at publication Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/12/42615874/why-is-cancer-focused-aadi-bioscience-stock-trading-higher-on-friday" target="_blank" rel="noreferrer noopener">Why Is Cancer-Focused Aadi Bioscience Stock Trading Higher On Friday?</a></li>
</ul>
This image was created using artificial intelligence MidJourney.

Analyst Color

Biotech

Health Care

PYXS

Pyxis Oncology's Deprioritizes Second Pipeline Asset, Analyst Applauds Move

SNPX

Synaptogenix shares are trading higher after the company announced it formed an independent Special Committee to explore strategic opportunities.

SCHL

Scholastic shares are trading lower after the company on Thursday reported worse-than-expected Q2 financial results.

BlackBerry shares are trading higher following Q3 financial results.

IONQ

IonQ shares are trading higher after Craig-Hallum raised its price target on the stock from $22 to $45 while maintaining a Buy rating.

HC Wainwright &amp; Co. analyst Patrick Trucchio reiterates Arrowhead Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARWR#NASDAQ">ARWR</a>) with a Buy and maintains $80 price target.

Reiteration

ARWR

HC Wainwright & Co. Reiterates Buy on Arrowhead Pharma, Maintains $80 Price Target

Looking for <a href="https://www.benzinga.com/trading-ideas/dividends">steady cash flow</a> in 2025? JPMorgan analysts have spotlighted four income-generating stock picks that offer dividend appeal and potential price upside. 
These are: Annaly Capital Management Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NLY#NYSE">NLY</a>), Corning Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GLW#NYSE">GLW</a>), Energy Transfer LP (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ET#NYSE">ET</a>) and HA Sustainable Infrastructure Capital Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HASI#NYSE">HASI</a>).
Here are the details on their top picks.
<h2 class="wp-block-heading">Annaly Capital</h2>
With a hefty forward dividend yield of 13.85% (per <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent122024&amp;t=be2bearmibe3na1">Benzinga Pro</a> data), Annaly Capital shines as a beacon for income seekers. 
Analyst Richard Shane expects the mortgage REIT to benefit from a gradual yield curve steepening and rising MBS prices as quantitative tightening eases. 
Trading near $19.76, NLY is viewed as a stable dividend play, supported by mid-teen ROEs and rising interest spreads, according to the analyst. His price target for 2025 is $20.
Read Also: <a href="https://www.benzinga.com/analyst-ratings/price-target/24/12/42615289/wall-streets-most-accurate-analysts-weigh-in-on-3-materials-stocks-delivering-high-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Weigh In On 3 Materials Stocks Delivering High-Dividend Yields</a>
<h2 class="wp-block-heading">Corning</h2>
Known for its innovation in glass and fiber optics, Corning offers more than shiny screens. 
Its modest 2.38% yield may seem subdued, but JPMorgan's Samik Chatterjee says this tech titan is poised for high-single-digit revenue growth. 
Riding on data center demand, telecom recovery, and AI-driven innovation, Corning's stock—currently at $48.18—has room to climb to $60 by the end of 2025, the analyst says.
<h2 class="wp-block-heading">Energy Transfer</h2>
Pipeline powerhouse Energy Transfer is turning heads with a forward dividend yield of 7.06%. 
Analyst Jeremy Tonet sees untapped value in its discounted EV/EBITDA ratio compared to peers. 
With fundamentals like Permian egress and natgas logistics firing on all cylinders, ET, trading at $18.70, appears poised to reach Tonet's $23 target, presenting a compelling opportunity for midstream investors.
<h2 class="wp-block-heading">HASI</h2>
Sustainability meets income in Hannon Armstrong Sustainable Infrastructure Capital. HASI's 6.29% yield sweetens the deal for this eco-friendly investment.
JPMorgan's Mark Strouse predicts a brighter outlook thanks to its KKR partnership and investment-grade rating. With shares at $28.72, Strouse forecasts a $42 price by 2025 as HASI reduces its reliance on public capital raises and executes on stable spreads.
Whether you're chasing high yields or balanced growth, these four income plays could be the backbone of your 2025 portfolio. 
From Annaly's robust dividends to Corning's AI-driven potential, JPMorgan's picks are all about turning steady streams into rivers of returns.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/12/42612794/djt-stock-plummets-over-5-following-trumps-stake-transfer-heres-more">DJT Stock Plummets Over 5% Following Trump&#8217;s Stake Transfer: Here&#8217;s More</a></li>
</ul>
Image created using artificial intelligence via Midjourney.

REIT

Dividends

Real Estate

Hannon Armstrong Sustainable Infrastructure Capital

HASI

4 Dividend Picks For 2025: JPMorgan's Top Income Stocks To Energize Your Portfolio

BCAB

BioAlta shares are trading lower after the company announced a $9.2 million registered direct offering of 9,679,158 shares at $1.19 per share.

Jefferies analyst Surinder Thind maintains Accenture (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACN#NYSE">ACN</a>) with a Hold and raises the price target from $355 to $385.

Jefferies Maintains Hold on Accenture, Raises Price Target to $385

Earnings week ahead: Walgreens Boots Alliance, Carnival, GameStop and more

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Eterna Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/erna-stock-quote/">ERNA</a>) just reported results for the first quarter of 2024.<ul><li>Eterna Therapeutics reported earnings per share of -$1.23.</li><li>The company reported revenue of $47,000.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/05/erna-stock-earnings-eterna-therapeutics-for-q1-of-2024/">ERNA Stock Earnings: Eterna Therapeutics Reported Results for Q1 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

ERNA Stock Earnings: Eterna Therapeutics Reported Results for Q1 2024

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Eterna Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/erna-stock-quote/">ERNA</a>) just reported results for the second quarter of 2024.<ul><li>Eterna Therapeutics reported earnings per share of -$1.02.</li><li>The company reported revenue of $47,000.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/erna-stock-earnings-eterna-therapeutics-for-q2-of-2024/">ERNA Stock Earnings: Eterna Therapeutics Reported Results for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

ERNA Stock Earnings: Eterna Therapeutics Reported Results for Q2 2024

Eterna Therapeutics ( ($ERNA) ) has issued an update. Eterna Therapeutics Inc. has entered into an exclusive licensing and collaboration agreement ...

Eterna Therapeutics Strikes Key Deal for Disease-Fighting Tech

Eterna (ERNA) Therapeutics announced the completion of a comprehensive financial restructuring of the Company with the aim to accelerate its develo...

Eterna completes strategic financial restructuring

Eterna Therapeutics regains Nasdaq compliance

Eterna (ERNA) Therapeutics has regained compliance with Nasdaq for continued listing and that its stock will continue to trade on The Nasdaq Stock ...

Eterna regains compliance with Nasdaq

Eterna Therapeutics announces up to $1 million stock repurchase program

Eterna (ERNA) Therapeutics announced that its Board of Directors has authorized a stock repurchase program of up to $1M of the company's outstandin...

Eterna announces up to $1M stock repurchase program

Eterna (ERNA) Therapeutics announced it will investigate the ability of its lead iMSC-based cell therapy, ERNA-101, to induce and modulate antitumo...

Eterna launches research to evaluate ERNA-101

AGRX

AMPE

APTO

AQMS

AREC

ASTS

ATNM

AULT

AXDX

AYRO

BLRX

BZFD

CMCL

CTAS

CWCO

DARE

DCTH

DLNG

DNMR

DOMH

DOYU

DTIL

ERNA

ESLT

GLPG

GREE

HEPS

IDEX

ITRM

LGMK

LITB

MAXN

MDAI

NCNO

NVVE

OGEN

ORGS

OUST

PAYS

PAYX

PLBY

REKR

RKDA

SMTC

STIX

TIVC

VIOT

VRNT

VSTM

VUZI

WPRT

XELA

XXII

Markets

Press Releases

Eterna Therapeutics Grants New President and CEO Sanjeev Luther Inducement Award Under Nasdaq Listing Rule 5635 (c)(4)

Management

Eterna Therapeutics Announces the Appointment of Peter Cicala, JD, to its Board of Directors

Eterna Therapeutics to Present at the ASGCT 27th Annual Meeting on the Development of a mRNA-Engineered iPSC Line which Mimics Native B2M Expression, via Targeted Insertion of HLA-E at the B2M Locus

Eterna Therapeutics to Present at the ASGCT 27th Annual Meeting on Development of Beta 2 Microglobulin-Knockout (B2M-KO) iMSC Line with Enhanced Immunosuppressive Activity and Stealthing Features that May Further Augment the Therapeutic Potential of MSCs in Inflammatory Diseases

Eterna Therapeutics Announces Appointment of Mahendra Rao, PhD, to its Scientific Advisory Board

Eterna Therapeutics Completes Strategic Financial Restructuring with the Aim to Accelerate its Developmental Activities and Long-Term Success

Eterna Therapeutics Regains Compliance with NASDAQ for Continued Listing

Eterna Therapeutics Announces Up to $1 Million Stock Repurchase Program

Eterna Therapeutics Launches Research to Evaluate its Lead Induced Mesenchymal Stem Cell Therapy Candidate's (ERNA-101) Ability to Induce and Modulate Antitumor Immunity in Ovarian Cancer and Breast Cancer Models

Comments

Eterna Therapeutics

Noticias

Últimas noticias sobre Eterna Therapeutics (NASDAQ:ERNA) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL